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ABSTRACT 
Aims: The purpose of this study was to define the most suitable cut-off point for fetal nuchal translucency 
thickness in a screening program for aneuploidy and trisomy 21 in the south of Vietnam. Material & Methods: 
Two thousand and five hundred cases of singleton pregnancies were followed prospectively from the first 
trimester to the delivery. The rate of aneuploidy was calculated by seeking a relationship to increased fetal 
nuchal translucency thickness then calculating the sensitivity and specificity of different cut-off points in 
thickness measurement to find the most suitable point for screening. 
Results: The prevalence of fetal abnormality was 1.5% (95% CI 1.1-2.1), and 1.2% (95% CI 0.8-1.7) of 
aneuploidy cases found and the commonest was trisomy 21. A cut-off point at 2.4 mm showed the highest level 
of sensitivity and specificity for the detection of aneuploidy (65.5 and 95.7%) and trisomy 21 (75.0 and 95.1%), 
with a false-positive rate of 4.3 and 4.9%, respectively. 
Conclusion: Using a cut-off point of nuchal translucency at 2.4 mm has potential for aneuploidy and trisomy 21 
screening in the south of Vietnam.  
Keywords: aneuploidy, cut-off point, fetal nuchal translucency thickness, first trimester, trisomy 21. 
 
INTRODUCTION 
In screening for trisomy 21 and other chromosomal abnormalities, measurement of nuchal translucency (NT) 
thickness in the first trimester between 45 to 84 mm of crown-rump length (CRL) (11.2 to 13.6 weeks of 
gestation), combined with maternal age and serum biochemistry, can be an effective method.
1-5 
The detection 
rate of these fetal chromosomal defects varied from 75 to 91% with a 1.0-5.4% false-positive rate when using the 
strategy of this combined test, this being shown in many countries.
6-9
 According to Brady et al., when fetal NT 
level increases the chance that a healthy baby will be born decreases.
10
 It is quite important to define the 
presence of an increased fetal NT thickness in the first trimester of gestation, because the fetal NT thickness 
increases as CRL increases.
2,6
 Therefore, many authors have proposed taking gestational age into account when 
determining whether a given NT thickness is considered as increased.
10-12
 
Many studies have asserted different cut-offs of NT for screening chromosomal aberration: some studies used a 
fixed cut-off of 3.0 mm with 75% of detection rate for trisomy 21 screening;
2,13
 others considered a NT at 2.5 
mm as a positive screening values with a 14.8% of positive predictive value;
14,15
 and recently, the use of the 95th 
percentile of NT thickness according to CRL (P95 CRL) showed a higher sensitivity for detecting chromosomal 
aberrations than using fixed cut-off point (3.0 mm) (70.9% of sensitivity with a 5.8% false-positive rate using a 
95th percentile method versus 54.8% sensitivity with a 3.5% false-positive rate using a fixed cut-off).
16,17
 The 
choice of fetal NT cut-off point depends on the strategy of prenatal screening and on the risk of the obstetrical 
population in each country. 
In this context, we carried out a prospective study to evaluate the distribution of fetal NT thickness and to define 
the most suitable cut-off point of fetal NT thickness for the predicting of the occurrence of aneuploidy and 




Between 1 January and 31 December 2009, all singleton pregnant women were offered fetal NT measurement 
and serum biochemistry in the first trimester (with CRL measurement from 45 to 84 mm) as part of routine 
prenatal care. The multi-pregnancies and nonviable fetuses were excluded from the study. The gestational age 
was calculated in weeks and days based on the results of CRL measurement in millimeters. Women also 
underwent a fetal morphological scanning routinely in the second trimester (18-24 weeks) for screening 
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structural malformation. 
Clinical testing 
The measurement of fetal NT was performed by sonographers trained and certified for measurement of fetal NT 
by the Fetal Medicine Foundation (FMF), UK guidelines. These sonographers had at least 5 years experience for 
ultrasound scan of fetal morphology. All pregnancies were carried out by using a transabdominal probe. Fetal 
NT was measured according to criteria of FMF: CRL was in range from 45 to 84 mm; fetus in sagittal position 
with spine situated posteriorly; fetus in neutral position with no hyperextension or flexion; NT clearly visible for 
measurement; and at least three fetal NT measurements were taken and the largest of the three measurements 
was recorded.
18
 An anatomic survey was done following a standardized protocol at the time of the fetal NT scan. 
All measurements were performed transabdominally by using SONOACE 8800 (MEDISON, Seoul, South 
Korea) and VOLUSON 730 PRO (GE, New York, NY, USA). The curved array (C7-3 or C5-2) transducer was 
equipped for fetal NT measurement in the first trimester and the 3D4-7EK transducer for fetal structural 
examination in the second trimester of gestation. 
Laboratory test 
For biochemistry test, the serum was separated and analyzed for free beta subunit of human chorionic 
gonadotropin and pregnancy-associated plasma protein-A using Immulite DPC (Diagnostic Products 
Cooperation) 2000 from Typolog Software Limited and Company KG (Tomesch, Germany). Based on maternal 
age, fetal NT thickness and serum markers, the risk of fetal chromosomal malformation (trisomy 21, trisomy 18) 
was calculated as combined test, following the results of Prisca software in Immulite DPC 2000 machine. A 
combined test was defined as positive at the threshold of 1 in 250 or more according to recommendation of Wald 




Fetal abnormality included the chromosomal aberrations that were diagnosed by amniocentesis and the structural 
defects that were detected by fetal ultra-sonography scanning in the first and/or the second trimester of gestation. 
Amniocentesis was considered as the 'gold standard' to diagnose aneuploidy. It was offered at 15-24 weeks of 
gestation and indicated to women who had a positive combined test (≥1/250), major fetal structural anomalies on 
the ultrasound examination systematically in the second trimester (18-24 weeks' gestation) and/or previous 
history of fetal or child chromosomal malformations. 
Statistics 
Results were expressed as mean and standard deviation for quantitative variables; the median and range was also 
determined. For categorical variables, a frequency table giving number and percentage of women in each 
category was established. 
The receiver operator characteristic (ROC) curve method and logistic regression analysis were applied to assess 
the association between aneuploidy and fetal NT thickness in order to find out an optimal cut-off point for 
diagnostic purposes. The sensitivity, specificity, positive predictive value and false-positive rate of different fetal 
NT cut-off point were calculated for both of aneuploidy and trisomy 21. 
Results were considered to be significant at the 5% critical level (P-value < 0.05). All calculations and analysis 




A total of 2500 singleton pregnancies were included in the study during the one-year investigation period. 
Among them, 1097 (43.9%) were primigravidas and the majority (67.0%) lived in an urban area (Table 1). None 
of the pregnancies resulted from assisted reproduction techniques, nor had an obstetrical history of fetus and/or 
child chromosomal abnormalities and none of the mothers were smokers. 
The risk of the abnormal baby was increased 2.7 times significantly (95% CI 1.1-6.0 and P < 0.01) in the group 
of advanced maternal age (≥35 years old). 
Fetal characteristics 
The fetal characteristics of the 2500 studied pregnancies in the first trimester of gestation are summarized in 
Table 2. 
Published in : Journal of Obstetrics and Gynaecology Research (2010) 
Status : Postprint (Author’s version) 
The percentage of amniocentesis in this study was 2.8% (71/2500) (95% CI 2.2-3.6%), with 2.7% (68/2500) 
(95% CI 2.1-3.4%) of positive serum biochemical test (above of 1/250) showing an essential indication of this 
invasive testing. There were no cases of chromosomal aberrations, which were diagnosed after birth. The 
prevalence of fetal abnormalities was 1.5% (38/2500) 
(95% CI 1.1-2.1%) and the incidence of abnormal karyotype amounted 1.2% (29/2500) (95% CI 0.8-1.7%). In 
these 29 cases of aneuploidy, the most frequent chromosomal aberration was trisomy 21 (16 cases) followed by 
trisomy 18 (7cases), as shown in Table 3. 
The fetal abnormalities, including fetal deaths, are detailed in Table 3, which also displays the distribution of 
gestation age, CRL and fetal NT thickness for each category. Table 3 shows that fetal NT thickness average 1.5 
± 0.4 mm in healthy fetuses and 2.7 ± 1.0 mm in the abnormal group. This difference was highly significant (P < 
0.0001). 
Correlation between fetal NT thickness and CRL 
As seen in Table 4, the distribution of fetal NT thickness values correlated well with CRL measurement (r = 
0.34, P = 0.001) (Fig. 1), in the sense that on average fetal NT thickness increased with the 5 mm interval 
defined CRL categories. Table 4 also gives the 95th percentile of fetal NT in each CRL category, the so-called 
P95(CRL) thresholds levels. These NT thresholds are adjusted for CRL and increase from 2.1 to 2.7 mm from 
the first to the last CRL category. 
Choice of fetal NT thickness for detecting fetal aneuploidy 
We established a logistic regression for calculation of risk index and probability of fetal aneuploidy: 
Logit = log(odds) = -9.149 + 2.569*NT (mm). 
In application of this formula, the odds = Pr(abnormal)/Pr(normal), the ratio of the risk (probability) of having an 
abnormal fetus and the chance of the fetus being normal. Since the coefficient of NT, namely 2.569, is positive, 
the odds increase with NT, in other terms: the higher NT, the greater the chances of having an abnormality (Fig. 
2). 
Similarly, in comparison of diagnostic value in different cut-off points of fetal NT, the point at 2.4 mm had the 
highest sensitivity and specificity for detection of fetal aberration and trisomy 21, with low false-positive rate 
(<5%) in our study population (Table 5). The ROC curve was drawn based on the sensitivity and specificity of 
fetal NT thickness and determined the cut-off point of 2.4 mm as the best acceptable point with an eligible area 
under ROC (0.86) (Fig. 3). 
Comparison of fetal abnormalities detected by using different fetal NT thickness cut-off points 
Table 6 compared the number of chromosomal abnormalities detected by using the four different fetal NT 
thickness cut-off points. When using the fetal NT thickness cut-off point of 2.4 mm, the detection rate of 
chromosomal defect and trisomy 21 was the highest (19/29 cases and 12/16 case, respectively) of the four cut-off 
points of fetal NT thickness. 
 
Table 1 Demographic characteristics of study pregnancies (n = 2500) 
 Mean ± SD Median Number (%) Range 
Maternal age (years) 28.9 ± 4.5 28.0  18-47 
≥35 years   302 (12.1)  
<35 years   2198 (87.9)  
Gestation  1.0  1-5 
1   1037 (41.5)  
2   1260 (50.4)  
≥3   203 (8.1)  
Parity  1.0  0-4 
0   1097 (43.9)  
1   1266 (50.6)  
2   135 (5.4)  
≥3   2 (0.1)  
Living environment     
Urban   1676 (67.04)  
Suburban   558 (22.32)  
Rural   266 (10.64)  
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SD, standard deviation. 
 
Table 2 Fetal characteristic in the first trimester (n = 2500) 
 Mean ± SD Median Range 
Gestational age 11.8 ± 0.6 12.1 11.0-13.6 
(weeks)    
CRL (mm) 55.4 ± 8.0 55.0 45-83 
BPD (mm) 20.3 ± 2.8 20.0 14-27 
NT (mm) 1.6 ± 0.5 1.5 0.7-6.0 
BPD, biparietal diameter; CRL, crown-rump length; NT, nuchal translucency; SD, standard deviation. 
 
Table 3 Characteristics of fetal abnormalities (n = 2500) 
 Number CRL (mm) Gestational age (weeks) Fetal NT thickness (mm) 
 (%) Mean ± SD Range Mean ± SD Range Mean ± SD Range 
Normal 2462 (98.48) 55.4 ± 8.0 45-83 11.9 ± 0.8 11.0-13.6 1.5 ± 0.4 0.7-4.8 
Abnormal 38 (1.52) 56.4 ± 6.8 45-66 11.9 ± 0.5 11.0-12.5 2.7 ± 1.0 0.8-6.0 
Fetal deaths 9 (0.36) 53.9 ± 7.3 45-66 11.7 ± 0.6 11.0-12.5 3.0 ± 0.3 2.5-3.5 
Aneuploidy 29 (1.16) 57.0 ± 6.7 45-66 11.6 ± 0.0 11.0-12.5 2.6 ± 1.1 0.8-6.0 
Trisomy 21 16 (0.64) 56.4 ± 7.5 45-66 12.0 ± 0.5 11.2-12.5 2.7 ± 1.1 0.8-6.0 
Trisomy 18 7 (0.28) 60.7 ± 3.1 58-65 12.3 ± 0.1 12.2-12.4 2.7 ± 1.0 1.7-4.8 
47,XXX 2 (0.08) 53.0 ± 0.0 53-53 11.6 ± 0.0 11.6-11.6 3.1 ± 1.3 2.1-4.0 
47,XXY 4 (0.16) 54.8 ± 7.9 45-63 11.8 ± 0.6 11.0-12.3 2.1 ± 1.4 0.9-4.0 
CRL, crown-rump length; NT, nuchal translucency; SD, standard deviation. 
 
 
Table 4 The mean ± SD and median of fetal NT according to 5 mm interval of CRL category (n = 2500) 
CRL Number Maternal age (years) CRL (mm) NT (mm) P95 (CRL) (mm) 
(mm)  Mean ± SD Median Mean ± SD Median Mean ± SD Median Mean ± SD Median 
45-49 818 28.9 ± 4.3 28 46.9 ± 1.9 46 1.4 ± 0.4 1.3 2.10 ± 0.04 2.1 
50-54 530 28.8 ± 4.6 28 52.9 ± 1.4 53 1.5 ± 0.4 1.4 2.23 ± 0.03 2.2 
55-59 490 29.2 ± 4.7 28 57.9 ± 1.4 58 1.6 ± 0.4 1.6 2.34 ± 0.03 2.3 
60-64 362 28.7 ± 4.3 28 62.8 ± 1.4 63 1.8 ± 0.5 1.7 2.45 ± 0.03 2.5 
65-69 199 28.1 ± 4.3 28 67.6 ± 1.5 67 1.8 ± 0.5 1.8 2.56 ± 0.03 2.5 
≥70 101 28.9 ± 4.1 29 74.2 ± 3.1 73 1.8 ± 0.4 1.8 2.71 ± 0.07 2.7 
Total 2500 28.9 ± 4.5 28 55.4 ± 8.0 55 1.6 ± 0.5 1.5 2.29 ± 0.18 2.5 
CRL, crown-rump length; NT, nuchal translucency; SD, standard deviation. 
 
Table 5 Sensitivity, specificity, positive predictive value (PPV), and false-positive rate (FPR) in different cut-off 
point of fetal NT thickness for detection aneuploidy and trisomy 21 
 NT cut-off point Specificity Sensitivity PPV FPR 
 (mm) (%) (%) (%) (%) 
Aneuploidy ≥2.4 95.7 65.5 15.2 4.3 
 ≥2.5 97.2 55.2 19.1 2.8 
 ≥3.0 99.4 17.2 25.0 0.6 
 ≥P95 (CRL) 95.9 58.6 14.4 4.1 
Trisomy 21 ≥2.4 95.1 75.0 9.0 4.9 
 ≥2.5 96.7 65.8 12.0 3.3 
 ≥3.0 99.1 12.5 8.33 0.9 
 ≥P95 (CRL) 95.4 68.8 8.37 4.6 
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Table 6 Fetal chromosomal abnormalities at the different cut-off point of fetal NT thickness (n = 2500) 
 Number Cut-off point of fetal NT thickness 
  ≥2.4mm ≥2.5 mm ≥3.0 mm ≥P95 (CRL) 
Normal 2462 107 70 19 104 
Fetal demised 9 7 6 0 5 
Aneuploidy 29 19 16 5 17 
Trisomy 21 16 12 11 2 11 
Trisomy 18 7 4 3 1 4 
47XXX 2 1 1 1 1 
47XXY 4 2 1 1 1 
Total 2500 133 92 24 126 
CRL, crown-rump length; NT, nuchal translucency. 
 
Figure 1 The distribution of fetal nuchal translucency (NT) thickness in corresponding to crown-rump length 
measurement. CI, confidence interval. 
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Figure 3 The receiver operator characteristic (ROC) curve of the fetal nuchal translucency (NT) thickness of 




This study showed that measurement of fetal NT thickness for screening chromosomal abnormalities can be 
potentially effective in the Vietnamese population. Using a cut-off point of 2.4 mm, the detection rate for 
aneuploidy was 65.5 with 4.3% of false-positive rate. 
The mean age of women in this study was 28.9 ± 4.5 years, a figure similar to that of Adekunle et al. (28.8 
years)
19
 and Souka et al. (29 years)
16
 who studied fetal abnormalities (included trisomy 21) in a population of 
low-risk pregnancies. Because 58% of babies with Down's syndrome were born to women aged ≥ 35 years,20 
advanced maternal age is one of the criterion defining a high-risk pregnancy. In our study, only 12.1% of women 
were in this category, hence reducing the influence of advanced maternal age on the incidence of this fetal 
abnormality. Moreover, most abnormalities (approximately 70%) occurred in the Tow-risk' group as in other 
studies,
2,21
 thus our results can be seen as representative of the Vietnamese population. 
An increasing relationship was highlighted between fetal NT thickness and gestation age (or CRL) as in 
previously published studies.
12,22-24
 The mean of NT thickness was 1.6 ± 0.5 mm, quite comparable to the values 
1.56 ± 0.41 mm by Hsu et al. in Taiwan,
12 
1.62 ± 0.5 mm by Chung et al. in South Korea,
22
 but was lower than 
results of Abele et al. (1.9 mm) in Germany
25
 and Acacio et al. (2.18 mm) in Brazil.
14
 In fact, there were no 
clinical relevant effects in NT measurements by ethnic origin following Adekunle et al., and Chen et al.
19,26
 Fetal 
NT thickness (in particular median and 95th percentile) adjusted for CRL measurement were not different from 
those found in the studies of Hsu et al. and Chung et al.
12,22
 Recently, Salomon et al. published reference charts 
and equations for fetal NT in a French population, based on a large sample of 19 198 fetal NT measurements. 
They found that the median of fetal NT thickness were comparable to those studied in other populations and the 
99th percentile was the same value as that reported by the FMF guidelines (around 3 mm).
18,24
 Abele et al. 
measured fetal NT thickness in a sample of fetuses with a larger CRL mean than our study: 63.3 mm (range 
45.0-84.0 mm) versus 55.4 mm (range 45.0-83.0 mm),
25
 whereas, Acacio et al. investigated fetal NT thickness in 
high-risk group women (whose average age were 35.8 years).
14 
Chorionic villus sampling is not done in our 
clinic, thus the amniocentesis was used as our 'gold standard' of diagnostic test for fetal aneuploidy (positive or 
negative) and to assess the efficacy of fetal NT thickness at the different cut-off points. Seventy-one (2.8%) 
women gave their consent to perform an amniocentesis. In fact, the rate of amniocentesis was influenced by the 
choice of different cut-off points for positive screening algorithms (1/200, 1/237, 1/307 ... of the combined test, 
integrated test, sequential screening, contingent screening, or triple test ... ).
27
 Based on each screening strategy 
and the risk of obstetrical population, the amniocentesis rate varied from 11% in France
28
 and 16% in the 
Parisian and Yveline's population,
21,29
 to 84.3% in China.
30
 We found 1.2% of fetal aneuploidy in our study. This 
prevalence of chromosomal aberration was similar to 1.2% by Chung et al.
22
 in South Korea and 1.91% by 
Zhang et al.'s report
30
 in China. However, our findings were higher than those studied by Romosan et al. in a 
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Swedish population (0.31%)
31
 and lower than those of Nicolaides et al. (3%), who chose a high-risk population 
(827 women of advanced maternal age, or family with history chromosomal abnormalities).
32
 
Since fetal NT thickness increases as CRL increases, it would seem necessary to account for this relation in 
predicting fetal chromosomal abnormalities, especially trisomy 21 from NT measurements.
2,12,22,23,33
 In the 
literature, many studies have recommended fetal NT thickness cut-off points such as 3.0 mm, 2.5 mm, 95th 
percentile or 99th percentile of distribution. The choice of suitable cut-off point depended on the sensitivity, 
specificity, positive predictive value and false-positive rate of the test in study population.
34
 Nicolaides et al. 
showed that fetal NT thickness ≥3.0 mm was an useful first trimester marker for fetal chromosomal 
abnormalities.
32
 Roberts et al. reported that if a NT cut-off ≥3 mm is used, 6% of unselected fetuses between 8 
and 13 weeks of gestation are classified as abnormal.
35 
The sensitivity of the cut-off at 3.0 mm for detecting 
trisomy 21 was reported to be 75% by Audibert et al.
13 
Recently, Alexioy et al. preferred to fix the cut-off point 
of fetal NT thickness at 2.5 mm for the detection of fetal chromosomal defects with a the positive predictive 
value of 14.8%.
15
 Acacio et al. also found 69.5 and 75% sensitivity for aneuploidy and for trisomy 21, 
alternatively, at the same threshold of 2.5 mm.
14
 To confirm the increase of fetal NT according to gestational age 
as stated by Snijder,
33
 Hsu et al. concluded that it was not appropriate to use a fixed cut-off point for NT 
thickness regardless of the gestational age in NT screening for Down's syndrome. They proposed when 
determining a given increase in NT thickness, it is essential to take the gestation age or CRL in to account.
12
 In 
addition, the sensitivity and the false-positive rate for total chromosomal aberrations by using of the P95 CRL-
dependent cut-off were 70.9 and 5.8%, respectively, as reported by Kim et al.
17
 
In many reports, the use of a cut-off point of 2.5 mm had been accepted with a the false-positive rate 5.5% in 
Scott et al.,
36
 5.7% in Pandya et al.
37
 and 6.3% in Jou et al.
38
 In our study, at 2.5 mm, we found a lower false-
positive rate (2.8%) than these authors and a higher positive predictive value (19.1%) than Alexioy et al. 
(14.8%).
15
 However, its sensitivity dropped abruptly by 10% in comparison to a cut-off at 2.4 mm (55.2 vs 
65.5%). Our study purpose was to assess the most suitable fetal NT cut-off point when screening for fetal 
chromosomal abnormalities (including trisomy 21) in pregnant Vietnamese women. It is clearly appropriate to 
select the fetal NT thickness cut-off point with the highest sensitivity and a false-positive rate (1 - specificity) 
less than 5%. By ROC curve analysis, we found that the cut-off point at 2.4 mm satisfied these conditions: 
65.5% sensitivity, 15.2% positive predictive value and 4.3% false positive. In addition, at 2.4 mm cut-off point, 
we increased the detection of number of chromosomal aberrations (14.3%, 19/133) and of trisomy 21 (12.8%, 
12/133). These results paralleled those of 14.8% of aneuploidy (18/122) and 9% of trisomy 21 (11/122) obtained 
by Alexioy et al., who selected 2.5 mm as the fixed cut-off point of increased fetal NT thickness.
15
 The study of 
Alexioy et al. reinforces our choice of 2.4 mm as the best fixed cut-off of increased fetal NT thickness for 
screening chromosomal abnormalities and trisomy 21. When using logistic regression analysis, a cut-off at 2.4 
mm corresponded to a probability of abnormal fetus of 5%, and probability of 95% normal fetus. The use of a 
fetal NT cut-off point at 2.4 mm has not been mentioned before in literature. 
With specific regards to trisomy 21 screening, we found 75% sensitivity and 95.13% specificity by using the NT 
thickness cut-off point at 2.4 mm. The sensitivity results was similar to that obtained by Pandya et al. in the 
United Kingdom,
37
 by Audibert F et al. in France,
13
 by Kim et al.
22
 in South Korea and by Acacio et al. in 
Brazil.
14
 With cut-off point of 2.4 mm, we also found that the rate of trisomy 21 was three times higher than 
trisomy 18 (12/16 cases of trisomy 21 vs 4/7 cases of trisomy 18) as reported by Acacio et al.
14
 
Recently, Fink et al. indicated that fetal NT thickness of 2 mm or more posed a significant risk for adverse 
perinatal outcome (adjusted OR 14.3; 95% CI 1.8-35; P < 0.001).
39
 This showed that the fetal NT cut-off point 




We conclude that an increased fetal NT of 2.4 mm corresponded to a suitable cut-off point for use in the existing 
screening program for detection of fetal abnormalities (especially trisomy 21) in the south of Vietnam. Since this 
is the first study into prediction of aneuploidy in Vietnam using fetal NT thickness, the fixed NT cut-off point at 
2.4 mm will be implemented routinely and assessed in other obstetric populations. 
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